X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8) 8
index medicus (8) 8
clinical neurology (7) 7
clinical trials (7) 7
oncology (7) 7
female (6) 6
glioblastoma (6) 6
male (6) 6
adult (5) 5
aged (5) 5
analysis (5) 5
glioblastoma multiforme (5) 5
medicine & public health (5) 5
middle aged (5) 5
antimitotic agents (4) 4
antineoplastic agents (4) 4
brain tumors (4) 4
neurology (4) 4
temozolomide (4) 4
abstracts (3) 3
abstracts from the 20th annual scientific meeting of the society for neuro-oncology (3) 3
adjuvant temozolomide (3) 3
bevacizumab (3) 3
cancer (3) 3
care and treatment (3) 3
gliomas (3) 3
radiation therapy (3) 3
radiotherapy (3) 3
research (3) 3
surgery (3) 3
survival (3) 3
academy (2) 2
american epilepsy society (2) 2
anticonvulsants - therapeutic use (2) 2
brain cancer (2) 2
brain neoplasms - complications (2) 2
brain neoplasms - drug therapy (2) 2
brain neoplasms - genetics (2) 2
brain tumor (2) 2
cancer therapies (2) 2
cell survival (2) 2
chemotherapy (2) 2
concomitant (2) 2
dendritic cells (2) 2
epidemiology (2) 2
follow-up studies (2) 2
gene expression (2) 2
glioblastoma - drug therapy (2) 2
glioma (2) 2
headache (2) 2
immunology (2) 2
immunotherapy (2) 2
keppra (2) 2
levetiracetam (2) 2
medical and health sciences (2) 2
medical prognosis (2) 2
medicine (2) 2
patients (2) 2
piracetam - analogs & derivatives (2) 2
piracetam - therapeutic use (2) 2
product development (2) 2
quality of life (2) 2
quality standards subcommittee (2) 2
retrospective studies (2) 2
risk (2) 2
seizures (2) 2
seizures - drug therapy (2) 2
seizures - etiology (2) 2
technology-assessment subcommittee (2) 2
therapeutics (2) 2
therapy (2) 2
tumors (2) 2
tyrosine kinase inhibitor (2) 2
vaccines (2) 2
acute chest-pain (1) 1
acute coronary syndrome - diagnosis (1) 1
acute coronary syndrome - epidemiology (1) 1
acute coronary syndromes (1) 1
acute myocardial-infarction (1) 1
age (1) 1
aged, 80 and over (1) 1
agents (1) 1
alanine (1) 1
alanine transaminase (1) 1
anesthesiology (1) 1
angiogenesis (1) 1
angiogenesis inhibitors (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
annual reports (1) 1
antagonist (1) 1
anti-epileptic (1) 1
antibodies (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antiepileptic drug levetiracetam (1) 1
antiepileptic drugs (1) 1
antigens (1) 1
antimalarials - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antitumor immunity (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 2055 - 2055
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 05/2018, Volume 16, Issue 1, pp. 1 - 9
Journal Article
JOURNAL OF NEURO-ONCOLOGY, ISSN 0167-594X, 05/2019, Volume 142, Issue 3, pp. 537 - 544
PurposePreclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including... 
TRIAL | SINGLE | ONCOLOGY | BEVACIZUMAB | NEWLY-DIAGNOSED GLIOBLASTOMA | Recurrent glioblastoma | Disulfiram | Clinical trial | Temozolomide | Copper | CLINICAL NEUROLOGY | Antimitotic agents | Clinical trials | Antineoplastic agents | Glioblastoma multiforme | Alanine | Toxicity | Transaminase | Glioblastoma | Alanine transaminase | Isocitrate dehydrogenase | Survival | Index Medicus
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2014, Volume 16, Issue Suppl 5, pp. v13 - v14
BACKGROUND: TPI 287, a novel anti-microtubule agent of the taxoid class that readily penetrates the blood-brain barrier, is under investigation for the... 
Abstracts
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e13026 - e13026
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2019, Volume 21, Issue Supplement_6, pp. vi28 - vi28
Abstract BACKGROUND GDC-0084 is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2014, Volume 16, Issue Suppl 5, pp. v90 - v90
Available treatments for recurrent glioblastoma (GBM) are inadequate, and median survival is approximately 6 months. Ipilimumab (ipi) is an immune modulator... 
Abstracts
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2014, Volume 16, Issue suppl 5, pp. v13 - v14
BACKGROUND: TPI 287, a novel anti-microtubule agent of the taxoid class that readily penetrates the blood-brain barrier, is under investigation for the... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2014, Volume 16, Issue suppl 5, pp. v90 - v90
Available treatments for recurrent glioblastoma (GBM) are inadequate, and median survival is approximately 6 months. Ipilimumab (ipi) is an immune modulator... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.